Literature DB >> 3984876

Intravenous urokinase in acute myocardial infarction.

D G Mathey, J Schofer, F H Sheehan, H Becher, V Tilsner, H T Dodge.   

Abstract

To achieve reperfusion early, an intravenous bolus of 2 million units of urokinase was administered in 50 patients with transmural acute myocardial infarction (AMI) 1.8 +/- 2.5 hours after the onset of symptoms. Coronary angiography performed 1.1 +/- 0.6 hours after urokinase therapy revealed patent coronary arteries in 30 patients (60%), with no significant difference between those with anterior and those with inferior AMI. Reocclusion occurred in only 1 of 24 patients restudied. Failure to achieve reperfusion was not related to the degree of systemic fibrinolytic activity, which was equally high in patients who did and those who did not achieve reperfusion, as evident from serially obtained fibrinogen measurements (77 +/- 52 vs 84 +/- 24 mg/dl, difference not significant). Plasmin activity, measured serially from 15 minutes to 24 hours after urokinase in 7 patients, was maximal at 15 minutes and undetectable after 3 hours. Wall motion at the infarct site measured from contrast ventriculograms was significantly better at follow-up only in patients in whom reperfusion was achieved and who received urokinase within 2 hours after the onset of symptoms as compared with patients in whom reperfusion was not achieved (-1.2 +/- 1.4 vs -2.4 +/- 0.9 standard deviations from normal, p less than 0.05). Peak serum creatine kinase level was significantly lower in patients in whom reperfusion was achieved than in those in whom it was not or those who had rethrombosis (802 +/- 763 vs 1,973 +/- 1,071 U/liter, p less than 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3984876     DOI: 10.1016/0002-9149(85)90710-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  Thrombolytic therapy in acute myocardial infarction.

Authors:  U Priglinger; K Huber
Journal:  Drugs Aging       Date:  2000-04       Impact factor: 3.923

Review 2.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

3.  Thrombolytic therapy for acute myocardial infarction. Lessons to be learned.

Authors:  S Sherry
Journal:  Tex Heart Inst J       Date:  1991

4.  Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration.

Authors:  H R Michels; J J Hoffman; F W Bär
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

5.  Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.

Authors:  W Kasper; T Meinertz; H Wollschläger; T Bonzel; C Chen; T Hofmann; A Zeiher; H Drexler; H Just
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Recent clinical developments in thrombolysis in acute myocardial infarction.

Authors:  J L Anderson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Experiences in intravenous urokinase treatment of 100 acute myocardial infarction patients.

Authors:  H Y Zhao; H B Li; L Wang; X H Zheng; H Wu
Journal:  J Tongji Med Univ       Date:  1991

Review 8.  Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Authors:  J Nazari; R Davison; K Kaplan; D Fintel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

Review 9.  Indications for coronary angioplasty in acute myocardial ischemic syndromes.

Authors:  P J de Feyter; P W Serruys; P G Hugenholtz
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

10.  Novel technique for the treatment of large subcapsular renal hematoma: combined use of percutaneous drainage and urokinase injection.

Authors:  Zhou Shen; Wenqiang He; Dong Liu; Feng Pan; Wencheng Li; Xiaomin Han; Bing Li
Journal:  Int Urol Nephrol       Date:  2014-04-13       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.